AVC

Manufacturer
Meda Pharmaceuticals
Effective date
2018-06-13
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
4
Source
legacy-cache
Hydrated at
2026-08-02 00:49:46

Label at a glance#

ProductAVC
Active ingredientSULFANILAMIDE
Label structure12 sections

Indications and uses

For the treatment of vulvovaginitis caused by Candida albicans . (See CLINICAL PHARMACOLOGY .)

Dosage and administration

One applicatorful (about 6 g) intravaginally once or twice daily. Improvements in symptoms should occur within a few days, but treatment should be continued for a period of 30 days. Douching with a suitable solution before insertion may be recommended for hygienic purposes.

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

AVC CREAM® (sulfanilamide) 15%

AVC® (sulfanilamide)

Cream

DESCRIPTION

DESCRIPTION SECTION

AVC® is a preparation for vaginal administration for the treatment of Candida albicans infections and available in the following form:

AVC Cream

Each tube contains:

Sulfanilamide.............................................................................................15.0%
in a water-miscible, non-staining base made from lactose, propylene glycol, stearic acid, diglycol stearate, methylparaben, propylparaben, trolamine, and water; buffered with lactic acid to an acid pH of approximately 4.3.

Sulfanilamide is an anti-infective agent. It is p-amino-benzenesulfonamide with the chemical structure:

sulfanilamide Chemical Structure
sulfanilamide Chemical Structure

Sulfanilamide occurs as a white odorless crystalline powder with a slightly bitter taste and sweet aftertaste. It is slightly soluble in water, alcohol, acetone, glycerin, propylene glycol, hydrochloric acid, and solutions of potassium and sodium hydroxide. It is practically insoluble in chloroform, ether, benzene, and petroleum ether.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Sulfanilamide has been a useful ingredient of vaginal formulations for about four decades. It blocks certain metabolic processes essential for the growth of susceptible bacteria. In AVC, the sulfanilamide is in a specially compounded base buffered to the pH (about 4.3) of the normal vagina to encourage the presence of the normally occurring Döderlein’s bacilli of the vagina.

The use of AVC for the treatment of vulvovaginitis caused by Candida albicans is supported by three clinical investigations. The three studies show AVC with sulfanilamide to be significantly more effective (p ≤ 0.01) than placebo as follows:

In Study I, the ratio of effectiveness was 71% for the AVC with sulfanilamide versus 49% for placebo with 30 days of treatment;

In Study II, the percentages were 48% and 24%, respectively, with 15 days of treatment;

In Study III, the percentages were 66% versus 33%, respectively, with 30 days of treatment.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

For the treatment of vulvovaginitis caused by Candida albicans. (See CLINICAL PHARMACOLOGY.)

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

AVC should not be used in patients known to be sensitive to this product or to the sulfonamides.

PRECAUTIONS

PRECAUTIONS SECTION

General

INFORMATION FOR PATIENTS SECTION

Because sulfonamides are absorbed from the vaginal mucosa, the usual precautions for oral sulfonamides apply. Patients should be observed for skin rash or evidence of systemic toxicity, and if these develop, the medications should be discontinued.

Deaths associated with administration of oral sulfonamides have reportedly occurred from hypersensitivity reactions, agranulocytosis, aplastic anemia, and other blood dyscrasias.

Goiter production, diuresis, and hypoglycemia have reportedly occurred rarely in patients receiving oral sulfonamides. Cross-sensitivity may exist with these agents. Rats appear to be especially susceptible to the goitrogenic effects of sulfonamides, and long-term administration has reportedly produced thyroid malignancies in this species.

Vaginal applicators or inserters should be used with caution after the seventh month of pregnancy.

Information For Patients

INFORMATION FOR PATIENTS SECTION

The doctor should advise the patient that in the event unusual local itching and burning occur, or other unusual symptoms develop, medication should be discontinued and not restarted without further consultation.

Drug Interactions

INFORMATION FOR PATIENTS SECTION

Drug interactions have not been documented with AVC.

Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

No data are available on long-term potential of AVC for carcinogenicity, mutagenicity, or impairment of fertility in animals or humans.

Pregnancy

PREGNANCY SECTION

Teratogenic Effects. Animal reproductive studies have been conducted with sulfonamides, including sulfanilamide (see below). It is not known whether AVC can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. AVC should be given to a pregnant woman only if clearly needed.

Sulfonamides, including sulfanilamide, readily pass through the placenta and reach fetal circulation. The concentration in the fetus is from 50-90% of that in the maternal blood and if high enough, can cause toxic effects. The safe use of sulfonamides, including sulfanilamide, in pregnancy has not been established. The teratogenic potential of most sulfonamides has not been thoroughly investigated in either animals or humans. However, a significant increase in the incidence of cleft palate and other bony abnormalities of offspring has been observed with certain sulfonamides of the short-, intermediate- and long-acting types (including sulfanilamide) when given to pregnant rats and mice at high oral doses (seven to 25 times the human therapeutic oral dose.)

Nursing Mothers

NURSING MOTHERS SECTION

Sulfanilamide should be avoided in nursing mothers because absorbed sulfonamides will appear in maternal milk and have caused kernicterus in the newborn. Because of the potential for serious adverse reactions in nursing infants from sulfonamides, a decision should be made whether to discontinue nursing or to discontinue the drug.

Pediatric Use

PEDIATRIC USE SECTION

Safety and effectiveness of AVC in pediatric patients have not been established.

ADVERSE REACTIONS SECTION

To report SUSPECTED ADVERSE REACTIONS, contact Meda Pharmaceuticals Inc. at 1-877-999-8403 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

ADVERSE REACTIONS

Local sensitivity reactions such as increased discomfort or a burning sensation have occasionally been reported following the use of topical sulfonamides. With the use of AVC Cream, sensitivity reactions (only local) were reported for 0.2% of the investigational patients.

Treatment should be discontinued if either local or systemic manifestations of sulfonamide toxicity or sensitivity occur.

DRUG ABUSE AND DEPENDENCE

DRUG ABUSE AND DEPENDENCE SECTION

Tolerance, abuse, or dependence with AVC have not been reported.

OVERDOSAGE

OVERDOSAGE SECTION

There have been no reports of accidental overdosage with AVC.

The acute oral LD50 of sulfanilamide is 3700-4200 mg/kg in mice.

The minimum human lethal dose of AVC has not been established.

It is not known if AVC is dialyzable.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

One applicatorful (about 6 g) intravaginally once or twice daily. Improvements in symptoms should occur within a few days, but treatment should be continued for a period of 30 days.

Douching with a suitable solution before insertion may be recommended for hygienic purposes.

HOW SUPPLIED

HOW SUPPLIED SECTION

AVC Cream

NDC 0037-6631-04 4 oz tube with applicator

Store at room temperature, below 86°F.

Protect from cold.

Product darkens with age. Potency is maintained throughout labeled shelf life when stored as directed.

This leaflet provides a summary of the important information about AVC Cream. You can get more information by calling the toll free number (1-877-999-8403).

Distributed by:

Meda Pharmaceuticals
Somerset, New Jersey 08873-4120

©2018 Mylan Specialty L.P.

AVC is a registered trademark of Meda Pharma S.A.R.L., a Mylan company.

141016
IN-663103-02
Rev. 6/2018

PRINCIPAL DISPLAY PANEL - PRODUCT CARTON LABEL

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 0037-6631-04   Rx only

4 ounces vaginal cream with applicator

AVC® CREAM
(sulfanilamide) 15%

Contains: sulfanilamide 15% in a water-miscible, non-staining base made from lactose,
propylene glycol, stearic acid, diglycol stearate, methylparaben, propylparaben, trolamine,
and water; buffered with lactic acid to an acid pH of approximately 4.3.

Usual dose: 1 applicatorful (about 6 g) intravaginally once or twice daily. Improvements in
symptoms should occur within a few days, but treatment should be continued for a
period of 30 days.

How to use cream applicator:

  1. Remove cap from tube. Invert cap and puncture seal of tube with point on top of cap.
  2. Screw plastic applicator on tube as far as it will go.
  3. Pull out plunger (inner rod) of applicator until it stops.
Carton Step 3
Carton Step 3
  1. Hold plunger out by placing thumb and forefinger on rod where it enters the barrel (outer cylinder). Squeeze tube from bottom with other hand until barrel is completely filled. Unscrew tube from applicator.
Carton Step 4
Carton Step 4
  1. Lying on your back, insert applicator into vagina as far as it will go comfortably without using force. Slowly push in plunger of applicator until it stops automatically.
  2. Carefully remove applicator from vagina, holding it by the barrel (outer cylinder).
Carton Step 6
Carton Step 6
  1. Wash applicator with warm, soapy water (do not boil). For easy cleaning, it may be disassembled by pulling plunger from barrel. Rinse and dry.

It is recommended that a pad be used to protect clothing.

Storage: Store at room temperature (below 86ºF).
Protect from cold.

Directions for use of applicator are printed under tear-away panel of carton.

Rx only.

Storage: Store at room temperature (below 86ºF).
Protect from cold.

Product darkens with age. Potency is maintained throughout labeled shelf life when stored as directed.

117404

Distributed by:
MEDA PHARMACEUTICALS®
Somerset, New Jersey 08873-4120

© 2018 Mylan Specialty L.P.

AVC is a registered trademark of Meda Pharma S.A.R.L., a Mylan
company

UC-663103-03
Rev. 5/2018

AVC Cream 15% Carton Label
AVC Cream 15% Carton Label

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
0037-6631-04GM - Gram0037-6631b5b3179a-f1c1-4c91-b5c2-879630f01f7812015-01-05

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
SULFANILAMIDEACTIVE INGREDIENT21240MF57M1
SULFANILAMIDEACTIVE MOIETY21240MF57M1
LACTIC ACIDINACTIVE INGREDIENT33X04XA5AT1
LACTOSE MONOHYDRATEINACTIVE INGREDIENTEWQ57Q8I5X1
METHYLPARABENINACTIVE INGREDIENTA2I8C7HI9T1
PEG-2 STEARATEINACTIVE INGREDIENT94YQ11Y95F1
PROPYLENE GLYCOLINACTIVE INGREDIENT6DC9Q167V31
PROPYLPARABENINACTIVE INGREDIENTZ8IX2SC1OH1
STEARIC ACIDINACTIVE INGREDIENT4ELV7Z65AP1
TROLAMINEINACTIVE INGREDIENT9O3K93S3TK1
WATERINACTIVE INGREDIENT059QF0KO0R1

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 11 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
0037-66310037-6631-04

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 10 matching rows.

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 6 · 333 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
LACTOSE MONOHYDRATELACTOSE MONOHYDRATEEWQ57Q8I5XINJECTION / INTRAMUSCULAR150 mgExact identifier — unii candidate
38 equally ranked IID candidates
STEARIC ACIDSTEARIC ACID4ELV7Z65APSOLUTION / TOPICALNAExact identifier — unii candidate
26 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3AEROSOL, FOAM / RECTAL1214 mgExact identifier — unii candidate
81 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHINJECTION / INTRALESIONAL0.02 %w/vExact identifier — unii candidate
68 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TSOLUTION / IRRIGATION2 %w/vExact identifier — unii candidate
79 equally ranked IID candidates
TROLAMINETROLAMINE9O3K93S3TKPOWDER / TOPICAL0.02 mg/mgExact identifier — unii candidate
22 equally ranked IID candidates
LACTIC ACIDLACTIC ACID33X04XA5ATINJECTION / INTRAVENOUS2232 mgExact identifier — unii candidate
18 equally ranked IID candidates
LACTOSE MONOHYDRATELACTOSE MONOHYDRATEEWQ57Q8I5XINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS690 mgExact identifier — unii candidate
38 equally ranked IID candidates
LACTOSE MONOHYDRATELACTOSE MONOHYDRATEEWQ57Q8I5XTABLET, FILM COATED, EXTENDED RELEASE / ORAL520 mgExact identifier — unii candidate
38 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3SOLUTION/ DROPS / OPHTHALMIC0.75 %w/vExact identifier — unii candidate
81 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3INJECTION, SOLUTION / SUBCUTANEOUS1.4 %w/vExact identifier — unii candidate
81 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TSOLUTION/ DROPS / OPHTHALMIC0.05 %w/vExact identifier — unii candidate
79 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3AEROSOL, FOAM / TOPICAL1800 mgExact identifier — unii candidate
81 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TJELLY / TOPICAL420 mgExact identifier — unii candidate
79 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TINJECTION / EPIDURAL1 mgExact identifier — unii candidate
79 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TDROPS / NASAL26 mgExact identifier — unii candidate
79 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TPOWDER, FOR SUSPENSION / ORAL75 mgExact identifier — unii candidate
79 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3CLOTH / TOPICAL0.03 mg/mgExact identifier — unii candidate
81 equally ranked IID candidates
TROLAMINETROLAMINE9O3K93S3TKSOLUTION / TOPICALNAExact identifier — unii candidate
22 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TEMULSION / TOPICAL0.2 %w/wExact identifier — unii candidate
79 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TJELLY / NASAL250 mgExact identifier — unii candidate
79 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHSYRUP / ORAL40 mgExact identifier — unii candidate
68 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TSOLUTION / TOPICAL216 mgExact identifier — unii candidate
79 equally ranked IID candidates
TROLAMINETROLAMINE9O3K93S3TKGEL, METERED / TRANSDERMAL14 mgExact identifier — unii candidate
22 equally ranked IID candidates
STEARIC ACIDSTEARIC ACID4ELV7Z65APAEROSOL, FOAM / VAGINAL4 %w/wExact identifier — unii candidate
26 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3GEL / VAGINAL750 mgExact identifier — unii candidate
81 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3TAMPON / VAGINAL62.1 mgExact identifier — unii candidate
81 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3CREAM / VAGINAL1225 mgExact identifier — unii candidate
81 equally ranked IID candidates
STEARIC ACIDSTEARIC ACID4ELV7Z65APOINTMENT / TOPICAL15 %w/wExact identifier — unii candidate
26 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3LIQUID / RESPIRATORY (INHALATION)10 %w/wExact identifier — unii candidate
81 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHSUSPENSION / AURICULAR (OTIC)NAExact identifier — unii candidate
68 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3ELIXIR / ORAL9306 mgExact identifier — unii candidate
81 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3SPRAY / NASAL5 mgExact identifier — unii candidate
81 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3SWAB / TOPICAL34.6 %w/wExact identifier — unii candidate
81 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHSOLUTION / NASAL140 mgExact identifier — unii candidate
68 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3OINTMENT / TOPICAL5148 mgExact identifier — unii candidate
81 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TAEROSOL, FOAM / TOPICAL0.16 %w/wExact identifier — unii candidate
79 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHCONCENTRATE / ORAL2.5 mg/5mlExact identifier — unii candidate
68 equally ranked IID candidates
LACTIC ACIDLACTIC ACID33X04XA5ATAEROSOL, FOAM / TOPICAL11 mgExact identifier — unii candidate
18 equally ranked IID candidates
TROLAMINETROLAMINE9O3K93S3TKSOLUTION / NASALNAExact identifier — unii candidate
22 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3SOLUTION / DENTAL2 %w/wExact identifier — unii candidate
81 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHSHAMPOO / TOPICAL0.03 %w/wExact identifier — unii candidate
68 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3FILM / BUCCAL1.48 mgExact identifier — unii candidate
81 equally ranked IID candidates
LACTIC ACIDLACTIC ACID33X04XA5ATCREAM / VAGINAL0.81 %w/wExact identifier — unii candidate
18 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHSOLUTION / RECTAL0.02 %w/vExact identifier — unii candidate
68 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHAEROSOL, FOAM / TOPICAL0.04 %w/wExact identifier — unii candidate
68 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHSOLUTION/ DROPS / OPHTHALMIC0.01 %w/vExact identifier — unii candidate
68 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TSOLUTION / IONTOPHORESIS0.1 %w/vExact identifier — unii candidate
79 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TGEL / TOPICAL24 mgExact identifier — unii candidate
79 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHTABLET / ORAL0.2 mgExact identifier — unii candidate
68 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHSPRAY / NASAL0.2 mgExact identifier — unii candidate
68 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3CREAM / TOPICAL76000 mgExact identifier — unii candidate
81 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3TABLET, FILM COATED, EXTENDED RELEASE / ORAL19 mgExact identifier — unii candidate
81 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TDROPS / ORAL1 mg/1mlExact identifier — unii candidate
79 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3OINTMENT, AUGMENTED / TOPICAL714 mgExact identifier — unii candidate
81 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3AEROSOL, FOAM / VAGINAL6.4 %w/wExact identifier — unii candidate
81 equally ranked IID candidates
STEARIC ACIDSTEARIC ACID4ELV7Z65APCAPSULE / ORAL90 mgExact identifier — unii candidate
26 equally ranked IID candidates
LACTOSE MONOHYDRATELACTOSE MONOHYDRATEEWQ57Q8I5XTABLET, DELAYED RELEASE / ORAL2313 mgExact identifier — unii candidate
38 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3LOTION / TOPICAL3392 mgExact identifier — unii candidate
81 equally ranked IID candidates
TROLAMINETROLAMINE9O3K93S3TKSPRAY / NASALNAExact identifier — unii candidate
22 equally ranked IID candidates

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 2 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
N006530-003AVCSULFANILAMIDE15% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**CREAM / VAGINALRLD1987-01-27
N006530-004AVCSULFANILAMIDE1.05GMSUPPOSITORY / VAGINAL1987-01-27

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 3 · 86 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08N006530-003AVC15% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**CREAM / VAGINALRLD1987-01-2784e616aacf4f…
2026-09-14 22:38:342026-08N006530-004AVC1.05GMSUPPOSITORY / VAGINAL1987-01-2784e616aacf4f…
2026-08-18 06:07:402026-07N006530-003AVC15% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**CREAM / VAGINALRLD1987-01-27caaa826d4ba7…
2026-08-18 06:07:402026-07N006530-004AVC1.05GMSUPPOSITORY / VAGINAL1987-01-27caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N006530-003AVC15% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**CREAM / VAGINALRLD1987-01-27011fe1cb6892…
2026-02-19 14:30 UTC2026-02N006530-004AVC1.05GMSUPPOSITORY / VAGINAL1987-01-27011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N006530-003AVC15% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**CREAM / VAGINALRLD1987-01-2731067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N006530-004AVC1.05GMSUPPOSITORY / VAGINAL1987-01-2731067a03dcf5…
2025-08-23 18:47 UTC2025-08N006530-003AVC15% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**CREAM / VAGINALRLD1987-01-276a471c1ec25d…
2025-08-23 18:47 UTC2025-08N006530-004AVC1.05GMSUPPOSITORY / VAGINAL1987-01-276a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N006530-003AVC15% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**CREAM / VAGINALRLD1987-01-27fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N006530-004AVC1.05GMSUPPOSITORY / VAGINAL1987-01-27fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N006530-003AVC15% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**CREAM / VAGINALRLD1987-01-27b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N006530-004AVC1.05GMSUPPOSITORY / VAGINAL1987-01-27b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N006530-003AVC15% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**CREAM / VAGINALRLD1987-01-2703ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N006530-004AVC1.05GMSUPPOSITORY / VAGINAL1987-01-2703ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N006530-003AVC15% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**CREAM / VAGINALRLD1987-01-272680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N006530-004AVC1.05GMSUPPOSITORY / VAGINAL1987-01-272680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N006530-003AVC15% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**CREAM / VAGINALRLD1987-01-275bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N006530-004AVC1.05GMSUPPOSITORY / VAGINAL1987-01-275bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N006530-003AVC15% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**CREAM / VAGINALRLD1987-01-27d8e5a09893c0…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N006530-004AVC1.05GMSUPPOSITORY / VAGINAL1987-01-27d8e5a09893c0…
2024-10-29 15:01 UTC2024-10N006530-003AVC15% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**CREAM / VAGINALRLD1987-01-27d06236e962d9…
2024-10-29 15:01 UTC2024-10N006530-004AVC1.05GMSUPPOSITORY / VAGINAL1987-01-27d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N006530-003AVC15% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**CREAM / VAGINALRLD1987-01-2779d66fd596c7…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N006530-004AVC1.05GMSUPPOSITORY / VAGINAL1987-01-2779d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N006530-003AVC15% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**CREAM / VAGINALRLD1987-01-27301d65b070ca…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N006530-004AVC1.05GMSUPPOSITORY / VAGINAL1987-01-27301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N006530-003AVC15% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**CREAM / VAGINALRLD1987-01-271e350fbaab3a…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N006530-004AVC1.05GMSUPPOSITORY / VAGINAL1987-01-271e350fbaab3a…
2024-05-31 18:47 UTC2024-05N006530-003AVC15% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**CREAM / VAGINALRLD1987-01-278072bd15b7f6…
2024-05-31 18:47 UTC2024-05N006530-004AVC1.05GMSUPPOSITORY / VAGINAL1987-01-278072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N006530-003AVC15%CREAM / VAGINALRLD1987-01-275c6f7cd8ea54…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N006530-004AVC1.05GMSUPPOSITORY / VAGINAL1987-01-275c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04N006530-003AVC15%CREAM / VAGINALRLD1987-01-275d02ea3f76ae…
2022-04-08 23:34 UTC2022-04N006530-004AVC1.05GMSUPPOSITORY / VAGINAL1987-01-275d02ea3f76ae…
2022-04-04 05:41 UTC2022-04N006530-003AVC15%CREAM / VAGINALRLD1987-01-274b0b4de00fa7…
2022-04-04 05:41 UTC2022-04N006530-004AVC1.05GMSUPPOSITORY / VAGINAL1987-01-274b0b4de00fa7…
2019-12-13 00:20 UTC2019-12N006530-003AVC15%CREAM / VAGINALRLD, RS1987-01-2774a2ff9319b5…
2019-12-13 00:20 UTC2019-12N006530-004AVC1.05GMSUPPOSITORY / VAGINAL1987-01-2774a2ff9319b5…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
7e724bec-38d4-41ae-ba9f-c2d29573160ad344f475-1bf2-4aaf-aae3-0cd0be4995d12018-06-13Adverse reactionsExact identifier
spl set id: d344f475-1bf2-4aaf-aae3-0cd0be4995d1

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.